Literature DB >> 27760255

Association of Preoperative Risk Factors With Malignancy in Pancreatic Mucinous Cystic Neoplasms: A Multicenter Study.

Lauren M Postlewait1, Cecilia G Ethun1, Mia R McInnis1, Nipun Merchant2, Alexander Parikh3, Kamran Idrees3, Chelsea A Isom3, William Hawkins4, Ryan C Fields4, Matthew Strand4, Sharon M Weber5, Clifford S Cho5, Ahmed Salem5, Robert C G Martin6, Charles Scoggins6, David Bentrem7, Hong J Kim8, Jacquelyn Carr8, Syed Ahmad9, Daniel E Abbott9, Gregory C Wilson9, David A Kooby1, Shishir K Maithel1.   

Abstract

Importance: Pancreatic mucinous cystic neoplasms (MCNs) harbor malignant potential, and current guidelines recommend resection. However, data are limited on preoperative risk factors for malignancy (adenocarcinoma or high-grade dysplasia) occurring in the setting of an MCN.
Objectives: To examine the preoperative risk factors for malignancy in resected MCNs and to assess outcomes of MCN-associated adenocarcinoma. Design, Setting, and Participants: Patients who underwent pancreatic resection of MCNs at the 8 academic centers of the Central Pancreas Consortium from January 1, 2000, through December 31, 2014, were retrospectively identified. Preoperative factors of patients with and without malignant tumors were compared. Survival analyses were conducted for patients with adenocarcinoma. Main Outcomes and Measures: Binary logistic regression models were used to determine the association of preoperative factors with the presence of MCN-associated malignancy.
Results: A total of 1667 patients underwent resection of pancreatic cystic lesions, and 349 (20.9%) had an MCN (310 women [88.8%]; mean (SD) age, 53.3 [14.7] years). Male sex (odds ratio [OR], 3.72; 95% CI, 1.21-11.44; P = .02), pancreatic head and neck location (OR, 3.93; 95% CI, 1.43-10.81; P = .01), increased radiographic size of the MCN (OR, 1.17; 95% CI, 1.08-1.27; P < .001), presence of a solid component or mural nodule (OR, 4.54; 95% CI, 1.95-10.57; P < .001), and duct dilation (OR, 4.17; 95% CI, 1.63-10.64; P = .003) were independently associated with malignancy. Malignancy was not associated with presence of radiographic septations or preoperative cyst fluid analysis (carcinoembryonic antigen, amylase, or mucin presence). The median serum CA19-9 level for patients with malignant neoplasms was 210 vs 15 U/mL for those without (P = .001). In the 44 patients with adenocarcinoma, 41 (93.2%) had lymph nodes harvested, with nodal metastases in only 14 (34.1%). Median follow-up for patients with adenocarcinoma was 27 months. Adenocarcinoma recurred in 11 patients (25%), with a 64% recurrence-free survival and 59% overall survival at 3 years. Conclusions and Relevance: Adenocarcinoma or high-grade dysplasia is present in 14.9% of resected pancreatic MCNs for which risks include male sex, pancreatic head and neck location, larger MCN, solid component or mural nodule, and duct dilation. Mucinous cystic neoplasm-associated adenocarcinoma appears to have decreased nodal involvement at the time of resection and increased survival compared with typical pancreatic ductal adenocarcinoma. Indications for resection of MCNs should be revisited.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27760255      PMCID: PMC5560258          DOI: 10.1001/jamasurg.2016.3598

Source DB:  PubMed          Journal:  JAMA Surg        ISSN: 2168-6254            Impact factor:   14.766


  29 in total

Review 1.  International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas.

Authors:  Masao Tanaka; Suresh Chari; Volkan Adsay; Carlos Fernandez-del Castillo; Massimo Falconi; Michio Shimizu; Koji Yamaguchi; Kenji Yamao; Seiki Matsuno
Journal:  Pancreatology       Date:  2006       Impact factor: 3.996

2.  Incidental pancreatic cysts: clinicopathologic characteristics and comparison with symptomatic patients.

Authors:  Carlos Fernández-del Castillo; Javier Targarona; Sarah P Thayer; David W Rattner; William R Brugge; Andrew L Warshaw
Journal:  Arch Surg       Date:  2003-04

3.  Pathologic examination accurately predicts prognosis in mucinous cystic neoplasms of the pancreas.

Authors:  R E Wilentz; J Albores-Saavedra; M Zahurak; M A Talamini; C J Yeo; J L Cameron; R H Hruban
Journal:  Am J Surg Pathol       Date:  1999-11       Impact factor: 6.394

4.  An aggressive surgical approach is warranted in the management of cystic pancreatic neoplasms.

Authors:  Jeffrey M Hardacre; Michael F McGee; Thomas A Stellato; James A Schulak
Journal:  Am J Surg       Date:  2007-03       Impact factor: 2.565

5.  A pancreatic mucinous cystadenoma in a man with mesenchymal stroma, expressing oestrogen and progesterone receptors.

Authors:  K Wouters; N Ectors; W Van Steenbergen; R Aerts; A Driessen; L Van Hoe; K Geboes
Journal:  Virchows Arch       Date:  1998-02       Impact factor: 4.064

Review 6.  Addressing the challenges of pancreatic cancer: future directions for improving outcomes.

Authors:  Manuel Hidalgo; Stefano Cascinu; Jörg Kleeff; Roberto Labianca; J-Matthias Löhr; John Neoptolemos; Francisco X Real; Jean-Luc Van Laethem; Volker Heinemann
Journal:  Pancreatology       Date:  2014-10-17       Impact factor: 3.996

7.  Clinicopathologic characteristics of 29 invasive carcinomas arising in 178 pancreatic mucinous cystic neoplasms with ovarian-type stroma: implications for management and prognosis.

Authors:  Kee-Taek Jang; Sang Mo Park; Olca Basturk; Pelin Bagci; Sudeshna Bandyopadhyay; Edward B Stelow; Dustin M Walters; Dong Wook Choi; Seoung Ho Choi; Jin Seok Heo; Juan M Sarmiento; Michelle D Reid; Volkan Adsay
Journal:  Am J Surg Pathol       Date:  2015-02       Impact factor: 6.394

8.  Mucinous cystic neoplasm of the pancreas: is surgical resection recommended for all surgically fit patients?

Authors:  Jae Woo Park; Jin-Young Jang; Mee Joo Kang; Wooil Kwon; Ye Rim Chang; Sun-Whe Kim
Journal:  Pancreatology       Date:  2014-01-08       Impact factor: 3.996

9.  Diagnosis of pancreatic cystic neoplasms: a report of the cooperative pancreatic cyst study.

Authors:  William R Brugge; Kent Lewandrowski; Elizabeth Lee-Lewandrowski; Barbara A Centeno; Tara Szydlo; Susan Regan; Carlos Fernandez del Castillo; Andrew L Warshaw
Journal:  Gastroenterology       Date:  2004-05       Impact factor: 22.682

10.  Mucinous cystic neoplasm of the pancreas is not an aggressive entity: lessons from 163 resected patients.

Authors:  Stefano Crippa; Roberto Salvia; Andrew L Warshaw; Ismael Domínguez; Claudio Bassi; Massimo Falconi; Sarah P Thayer; Giuseppe Zamboni; Gregory Y Lauwers; Mari Mino-Kenudson; Paola Capelli; Paolo Pederzoli; Carlos Fernández-del Castillo
Journal:  Ann Surg       Date:  2008-04       Impact factor: 12.969

View more
  23 in total

1.  The diagnosis of pancreatic mucinous cystic neoplasm and associated adenocarcinoma in males: An eight-institution study of 349 patients over 15 years.

Authors:  Cecilia G Ethun; Lauren M Postlewait; Mia R McInnis; Nipun Merchant; Alexander Parikh; Kamran Idrees; Chelsea A Isom; William Hawkins; Ryan C Fields; Matthew Strand; Sharon M Weber; Clifford S Cho; Ahmed Salem; Robert C G Martin; Charles R Scoggins; David Bentrem; Hong J Kim; Jacquelyn Carr; Syed A Ahmad; Daniel E Abbott; Gregory Wilson; David A Kooby; Shishir K Maithel
Journal:  J Surg Oncol       Date:  2017-02-17       Impact factor: 3.454

2.  Benign Tumors of the Pancreas-Radical Surgery Versus Parenchyma-Sparing Local Resection-the Challenge Facing Surgeons.

Authors:  Hans G Beger
Journal:  J Gastrointest Surg       Date:  2018-01-03       Impact factor: 3.452

Review 3.  Fibroblasts in Pancreatic Ductal Adenocarcinoma: Biological Mechanisms and Therapeutic Targets.

Authors:  Martin C Whittle; Sunil R Hingorani
Journal:  Gastroenterology       Date:  2019-02-02       Impact factor: 22.682

Review 4.  [Diagnostics and clinical management of premalignant diseases of the pancreas].

Authors:  S M Buchholz; C Ammer-Herrmenau; V Ellenrieder; A Neesse
Journal:  Internist (Berl)       Date:  2022-03-02       Impact factor: 0.743

Review 5.  [Pancreatic cystic space-occupying lesions-Diagnostics, treatment and follow-up care : Current recommendations taking the current German S3 guidelines on pancreatic cancer into account].

Authors:  Maximilian Brunner; Lena Häberle; Irene Esposito; Robert Grützmann
Journal:  Chirurg       Date:  2022-03-22       Impact factor: 0.955

6.  Pancreatic mucinous cystic neoplasms located in the distal pancreas: a multicenter study.

Authors:  Jose M Ramia; Juan Del Rio Martín; Gerardo Blanco-Fernández; Miguel Cantalejo-Diaz; Fernando Pardo; Elena Muñoz-Forner; Alberto Carabias; Alba Manuel-Vazquez; Pedro J Hernández-Rivera; Isabel Jaén-Torrejimeno; Helga K Kälviäinen-Mejia; Fernando Rotellar-Sastre; Marina Garcés-Albir; Raquel Latorre; Texell Longoria-Dubocq; Noelia De Armas-Conde; Alejandro Serrablo-Requejo; Sara Esteban Gordillo; Luis Sabater; Mario Serradilla-Martín
Journal:  Gland Surg       Date:  2022-05

7.  Translation of a Protease Turnover Assay for Clinical Discrimination of Mucinous Pancreatic Cysts.

Authors:  Vallabh Suresh; Kaleb Byers; Ummadisetti Chinna Rajesh; Francesco Caiazza; Gina Zhu; Charles S Craik; Kimberly Kirkwood; Vincent Jo Davisson; Daniel A Sheik
Journal:  Diagnostics (Basel)       Date:  2022-05-28

Review 8.  ACG Clinical Guideline: Diagnosis and Management of Pancreatic Cysts.

Authors:  Grace H Elta; Brintha K Enestvedt; Bryan G Sauer; Anne Marie Lennon
Journal:  Am J Gastroenterol       Date:  2018-02-27       Impact factor: 10.864

Review 9.  Pancreatic Cystic Neoplasms: Different Types, Different Management, New Guidelines.

Authors:  Lianne Scholten; Nadine C M van Huijgevoort; Jeanin E van Hooft; Marc G Besselink; Marco Del Chiaro
Journal:  Visc Med       Date:  2018-06-08

10.  Diagnostic Concordance and Preoperative Risk Factors for Malignancy in Pancreatic Mucinous Cystic Neoplasms.

Authors:  Ga Hee Kim; Kyu Choi; Namyoung Paik; Kyu Taek Lee; Jong Kyun Lee; Kwang Hyuck Lee; In Woong Han; Soo Hoon Kang; Jin Seok Heo; Joo Kyung Park
Journal:  Gut Liver       Date:  2021-12-21       Impact factor: 4.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.